Biotechnology

Biotechnology

Topic

Heard in 6 episodes across 6 shows since Nov 2026

Biotechnology is a multidisciplinary field combining biology, natural sciences, and engineering to use living organisms, cells, and biological molecules to develop products and services. It includes applications in medicine and pharmaceuticals, agriculture, food production, environmental science, and industrial processes; in the podcast context, “biotech” most often refers to biotechnology companies, scientific development pipelines, and their investment prospects, including the effects of AI on research and investing.

Discussed inMarkets100%

Episodes

6
across 6 shows

This week

0
episodes on 0 shows

Expert statements

6
2 positive · 4 negative

Share of the conversation

Mentions of Biotechnology per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.03‰0.05‰0.07‰0.1‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Nov 100.01‰1
Nov 120.02‰2
Nov 150.05‰3
Nov 170.07‰4
Nov 210.09‰4

The full trend: rank, tone and why it is trending →

Email alert

Email me when Biotechnology comes up on a podcast

One email a week at most, with the new episodes that mention Biotechnology. Free, no account needed, unsubscribe in one click.

What experts have said about Biotechnology

6 statements · 2 positive · 4 negative

  1. Simone FishburnNegativeNov 20, 2026· BioCentury This Week

    European investors may need U.S. crossover or U.S.-based investors for NASDAQ listings.

    “if they ever want to go public on NASDAQ, you know, a premise that they have to do. They're not going to be able to do that if they don't have U.S. crossovers or U.S.-based investors.”

    Listen at 20:07

    Open the episode · Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation
  2. Greg SivanovichPositiveNov 20, 2026· Biotech Hangout

    Biotechs should announce financings immediately after positive data to capture value.

    “when you have good data, you should announce a financing right away because if you let the market sit, given the broader... market, you may not be able to capture value”

    Listen at 49:46

    Open the episode · Episode 204 - November 20, 2026
  3. Hemant TanejaNegativeNov 19, 2026· TBPN

    Biotech markets do not properly incentivize building large independent businesses.

    “I actually don't think the incentive structures and markets are set up the right way to go do that.”

    Listen at 1:24:30

    Open the episode · Anthropic IPO, GTA 6 Launch, Strauss Zelnick Joins | Hemant Taneja

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

6 episodes featuring Biotechnology, newest first

Biotechnology · PodLume